Dharminder Singh Chahal
Director/Board Member chez MENDUS AB
Fortune : 537 424 $ au 31/03/2024
Profil
Mr. Dharminder Singh Chahal is an Independent Director at Mendus AB, a Fund Manager at Swanbridge Capital Management BV, a Chairman-Supervisory Board at DCPrime BV, a Chief Executive Officer at SkylineDx BV, a Chief Executive Officer & Owner at Exponential BV, an Investment Manager at Van Herk Investments BV and a Managing Director at Sairopa B V.
He is on the Board of Directors at Mendus AB, Sensara BV, Anemones Hospitality & Hotels Pvt Ltd., Ceradis BV, Gilde Healthcare II Management BV, Gilde Healthcare III Management BV, VitalneXt BV, Medis Medical Imaging Systems BV and Pan Cancer T.
Mr. Chahal was previously employed as an Independent Member-Supervisory Board by Dr. Reddy's Research & Development BV and a Chief Executive Officer by Quorics BV.
He also served on the board at BioInvent International AB, Agendia, Inc., Creative Antibiotics AB, deVGen NV, Innate Pharma SA and Isobionics BV.
He received his graduate degree from Erasmus University Rotterdam and a graduate degree from Delft University of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 300 000 ( 0,46% ) | 476 964 $ | 31/03/2024 | |
MENDUS AB
0,21% | 31/12/2022 | 1 436 448 ( 0,21% ) | 60 460 $ | 31/03/2024 |
Postes actifs de Dharminder Singh Chahal
| Sociétés | Poste | Début |
|---|---|---|
| MENDUS AB | Director/Board Member | 22/01/2021 |
Pan Cancer T
 Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Director/Board Member | - |
Sensara BV
 Sensara BV Internet Software/ServicesTechnology Services Sensara BV engages in the development of self-learning, intelligent home monitoring solutions for the home care industry. It offers a smart sensor system, which detects unusual situations and sounds an alarm when something is wrong. The company was founded by Irek Karkowski and Ted Punt and is headquartered in Rotterdam, the Netherlands. | Director/Board Member | 01/04/2020 |
Medis Medical Imaging Systems BV
 Medis Medical Imaging Systems BV Packaged SoftwareTechnology Services Medis Medical Imaging Systems BV engages in the development and supply of software solutions for data imaging used by medical industry. Its products include Media Suite MR, Media Suite XA, Medis Suite CT, and Intravascular. The company was founded by Johan Hans C. Reiber in 1989 and is headquartered in Leiden, the Netherlands. | Director/Board Member | - |
| Anemones Hospitality & Hotels Pvt Ltd. | Director/Board Member | - |
Ceradis BV
 Ceradis BV Chemicals: AgriculturalProcess Industries Ceradis BV develops and markets environmental solutions for plant nutrition, crop protection, and formulation services. It focuses on the use of biological formulation additives and the development of biofungicides based on macro-organisms or natural products. The company was founded by Wim M. van der Krieken in 2005 and is headquartered in Wageningen, the Netherlands. | Director/Board Member | - |
Swanbridge Capital Management BV
 Swanbridge Capital Management BV Investment ManagersFinance Swanbridge Capital Management is a venture capital firm, headquartered in Netherland. The frim founded in 2016 by Van Herk Investments, the Erasmus Medical Center and the City of Rotterdam. | Private Equity Investor | 01/12/2016 |
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Chairman | 01/10/2014 |
| Gilde Healthcare III Management BV | Director/Board Member | - |
| ░░░░░ ░░░░░░░░░░ ░░ ░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Dharminder Singh Chahal
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Dharminder Singh Chahal
| Erasmus University Rotterdam | Graduate Degree |
| Delft University of Technology | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| INNATE PHARMA | Health Technology |
| MENDUS AB | Health Technology |
| Entreprise privées | 20 |
|---|---|
Creative Antibiotics AB
 Creative Antibiotics AB Pharmaceuticals: MajorHealth Technology Creative Antibiotics AB engages in the manufacture of pharmaceuticals products. The company was founded in 2000 and is headquartered in Umeå, Sweden. | Health Technology |
Van Herk Investments BV
 Van Herk Investments BV Investment ManagersFinance Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands. | Finance |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Health Technology |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Health Technology |
Isobionics BV
 Isobionics BV Chemicals: Major DiversifiedProcess Industries Isobionics BV operates as a holding company, which produces flavor and fragrance ingredients. The firm manufactures and supplies natural chemical substances such as Valencene, Nootkatone, and Beta-Elemene. The company was founded by Toine Janssen in 2008 and is headquartered in Geleen, the Netherlands. | Process Industries |
| Gilde Healthcare II Management BV | |
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Health Technology |
Ceradis BV
Ceradis BV Chemicals: AgriculturalProcess Industries Ceradis BV develops and markets environmental solutions for plant nutrition, crop protection, and formulation services. It focuses on the use of biological formulation additives and the development of biofungicides based on macro-organisms or natural products. The company was founded by Wim M. van der Krieken in 2005 and is headquartered in Wageningen, the Netherlands. | Process Industries |
Medis Medical Imaging Systems BV
Medis Medical Imaging Systems BV Packaged SoftwareTechnology Services Medis Medical Imaging Systems BV engages in the development and supply of software solutions for data imaging used by medical industry. Its products include Media Suite MR, Media Suite XA, Medis Suite CT, and Intravascular. The company was founded by Johan Hans C. Reiber in 1989 and is headquartered in Leiden, the Netherlands. | Technology Services |
| Gilde Healthcare III Management BV | |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Exponential BV
 Exponential BV Miscellaneous Commercial ServicesCommercial Services Exponential BV is a Dutch company that provides management and business consulting services. The private company is based in Capelle aan de IJssel, Netherlands. The CEO of the company is Dharminder S. Chahal. | Commercial Services |
Quorics BV
 Quorics BV BiotechnologyHealth Technology Quorics BV develops novel therapeutics and early diagnostic tests for cardiovascular diseases. The company was founded by Dharminder S. Chahal in 2012 and is headquartered in Rotterdam, the Netherlands. | Health Technology |
VitalneXt BV
 VitalneXt BV Pharmaceuticals: GenericHealth Technology VitalneXt BV develops retails and manufactures products for healthy ageing. Its products include promanna, vital01 and other products. The firm develops products with evidence-based health benefits for the ageing population. It also develops new, proprietary, technologies, ingredients and products through its own network and through collaborations with the company's research partners. The company was founded by Rein Strijker in May 2013 and is headquartered in Amersfoort, the Netherlands. | Health Technology |
SkylineDx BV
 SkylineDx BV Medical/Nursing ServicesHealth Services SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands. | Health Services |
Swanbridge Capital Management BV
Swanbridge Capital Management BV Investment ManagersFinance Swanbridge Capital Management is a venture capital firm, headquartered in Netherland. The frim founded in 2016 by Van Herk Investments, the Erasmus Medical Center and the City of Rotterdam. | Finance |
Sensara BV
Sensara BV Internet Software/ServicesTechnology Services Sensara BV engages in the development of self-learning, intelligent home monitoring solutions for the home care industry. It offers a smart sensor system, which detects unusual situations and sounds an alarm when something is wrong. The company was founded by Irek Karkowski and Ted Punt and is headquartered in Rotterdam, the Netherlands. | Technology Services |
| Anemones Hospitality & Hotels Pvt Ltd. | |
Pan Cancer T
Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Health Technology |
Sairopa B V
 Sairopa B V MiscellaneousMiscellaneous Sairopa B V is a Dutch company that develops medicines and operates as an investment holding company. | Miscellaneous |
